Ernexa Therapeutics Inc..
ERNA.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
Ernexa Therapeutics Inc. is a biopharmaceutical company focused on the discovery and development of novel therapeutics. The company's primary focus is on developing innovative treatments for diseases with unmet medical needs. This involves research and experimental development activities in the fiel...Show More
Better Health for All
10
Ernexa Therapeutics Inc. is entirely focused on developing novel cell therapies for advanced cancer and autoimmune diseases, including ERNA-101 for ovarian cancer and ERNA-201 for autoimmune disease.
1
This indicates that 100% of its product portfolio is devoted to health improvement, aligning with the 'entire business devoted to health improvement' criterion. There is no evidence of revenue from products with negative health outcomes, and the company's business model is oriented toward health improvement, which maps to the highest positive tier for harmful revenue share. The company aims to enable scalable manufacturing and broad patient accessibility for its therapies.
2
Ernexa is developing innovative cell therapies using induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs), but no specific percentage of R&D budget is provided.
3
The company has successfully completed a Pre-Investigational New Drug Application (Pre-IND) meeting with the FDA, receiving regulatory alignment for its development approach, but this does not provide sufficient detail to score clinical trial ethics.
4
Fair Money & Economic Opportunity
0
No evidence available to assess Ernexa Therapeutics Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No evidence was found in the provided articles regarding Ernexa Therapeutics Inc. (ERNA.US) or its performance against any of the 'Fair Pay & Worker Respect' KPIs.
1
All articles focused on Tesla's environmental performance.
2
Fair Trade & Ethical Sourcing
0
No information regarding fair trade, ethical sourcing, or related metrics such as fair-trade certification, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed, ethical clause coverage in contracts, materials risk index, or supplier diversity spend was found in the provided articles for Ernexa Therapeutics Inc.
1
Honest & Fair Business
-40
Ernexa Therapeutics Inc. had a material weakness in its internal control over financial reporting as of and for the year ended December 31, 2023, related to a lack of technical accounting proficiency in complex matters.
1
This led to one financial restatement for 2023 and the dismissal of Grant Thornton LLP as its independent registered public accounting firm on June 30, 2025, followed by the engagement of Haskell & White LLP on July 1, 2025.
2
The company has implemented a confidential and anonymous financial concern hotline, as required by the SEC, for complaints regarding accounting, internal accounting controls, or auditing matters, which allows for encrypted communication and status updates.
3
Additionally, Ernexa Therapeutics regained compliance with Nasdaq's minimum bid price requirement on July 1, 2025.
4
Kind to Animals
-50
Ernexa Therapeutics Inc. conducts animal testing, including an Embryofetal Development (EFD) study on pregnant rabbits using three dose levels of Occidiofungin gel.
1
The company also used mice to develop an ovarian tumor model, injecting ID8 cells intraperitoneally and treating them with ERNA-101.
2
The EFD study was conducted in accordance with international regulatory guidelines (ICH S5(R3)).
3
While a policy on animal testing exists, its details regarding scope, strength, or enforcement are not provided, and there are no transparent reduction targets for animal testing volume.
4
No War, No Weapons
0
No evidence available to assess Ernexa Therapeutics Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, concrete data points related to environmental performance, climate action, resource use, or sustainability initiatives for Ernexa Therapeutics Inc. (ERNA.US) were found across the provided articles.
1
The articles primarily contain financial information, SEC filing details, and general company descriptions, none of which provide measurable evidence for any of the 'Planet-Friendly Business' KPIs.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding Ernexa Therapeutics Inc.'s performance on any of the KPIs related to Respect for Cultures & Communities. The articles primarily focused on financial news, company developments, or were unavailable for analysis, thus providing no evidence for scoring.
1
Safe & Smart Tech
0
No evidence available to assess Ernexa Therapeutics Inc. on Safe & Smart Tech.
Zero Waste & Sustainable Products
0
No evidence available to assess Ernexa Therapeutics Inc. on Zero Waste & Sustainable Products.